Comparative Pharmacology
Head-to-head clinical analysis: BAL versus VISTOGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAL versus VISTOGARD.
BAL vs VISTOGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Uridine triacetate is a prodrug of uridine, which competes with fluorouracil (5-FU) catabolites for binding to orotate phosphoribosyltransferase, reducing the incorporation of 5-FU metabolites into RNA and DNA, thereby preventing cell death.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
6 g (2 vials) intravenously over 15 minutes as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Clinical Note
moderateBalsalazide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Acetyldigitoxin
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Ouabain
The terminal elimination half-life of uridine triacetate metabolites (primarily uridine and its metabolites) is approximately 2-3 hours. This short half-life supports the need for multiple daily doses (typically 10 doses over 5 days) to maintain therapeutic uridine concentrations.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Vistogard (uridine triacetate) is primarily excreted via the kidneys as inactive metabolites, with approximately 90% of the administered dose recovered in urine within 24 hours. The remainder is eliminated via feces (about 10%).
Category C
Category C
Chelating Agent
Chelating Agent
"The serum concentration of Ouabain can be decreased when it is combined with Balsalazide."